AiPD: Autoinhibited Protein Database

P17980

Gene name	PSMC3 (TBP1)
Protein name	26S proteasome regulatory subunit 6A
Names	26S proteasome AAA-ATPase subunit RPT5, Proteasome 26S subunit ATPase 3, Proteasome subunit P50, Tat-binding protein 1, TBP-1
Species	Homo sapiens (Human)
KEGG Pathway	hsa:5702
EC number
Protein Class

Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

1-219 (Predicted disordered autoinhibitory region) PR

Target domain
Relief mechanism
Assay	cis-regPred

AID

1-219 (Predicted disordered autoinhibitory region)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

References

Yeon JH et al. (2016) "Systems-wide Identification of cis-Regulatory Elements in Proteins", Cell Systems, 2, 89-100

Autoinhibited structure

Activated structure

60 structures for P17980

Entry ID	Method	Resolution	Chain	Position	Source
5GJQ	EM	450 A	M	1-439	PDB
5GJR	EM	350 A	0/M	1-439	PDB
5L4G	EM	402 A	M	1-439	PDB
5LN3	EM	680 A	M	1-439	PDB
5M32	EM	380 A	g	1-439	PDB
5T0C	EM	380 A	AF/BF	1-439	PDB
5T0G	EM	440 A	F	1-439	PDB
5T0H	EM	680 A	F	1-439	PDB
5T0I	EM	800 A	F	1-439	PDB
5T0J	EM	800 A	F	1-439	PDB
5VFP	EM	420 A	F	44-439	PDB
5VFQ	EM	420 A	F	44-439	PDB
5VFR	EM	490 A	F	44-439	PDB
5VFS	EM	360 A	F	1-439	PDB
5VFT	EM	700 A	F	63-439	PDB
5VFU	EM	580 A	F	63-439	PDB
5VGZ	EM	370 A	F	53-167	PDB
5VHF	EM	570 A	F	53-432	PDB
5VHH	EM	610 A	F	53-432	PDB
5VHI	EM	680 A	F	53-432	PDB
5VHJ	EM	850 A	F	166-432	PDB
5VHM	EM	830 A	F	166-432	PDB
5VHN	EM	730 A	F	166-432	PDB
5VHO	EM	830 A	F	166-432	PDB
5VHP	EM	790 A	F	166-432	PDB
5VHQ	EM	890 A	F	166-432	PDB
5VHR	EM	770 A	F	166-432	PDB
5VHS	EM	880 A	F	53-432	PDB
6MSB	EM	300 A	F	1-439	PDB
6MSD	EM	320 A	F	1-439	PDB
6MSE	EM	330 A	F	1-439	PDB
6MSG	EM	350 A	F	1-439	PDB
6MSH	EM	360 A	F	1-439	PDB
6MSJ	EM	330 A	F	1-439	PDB
6MSK	EM	320 A	F	1-439	PDB
6WJD	EM	480 A	F	1-439	PDB
6WJN	EM	570 A	F	44-439	PDB
7QXN	EM	370 A	F	1-439	PDB
7QXP	EM	360 A	F	1-439	PDB
7QXU	EM	430 A	F	1-439	PDB
7QXW	EM	410 A	F	1-439	PDB
7QXX	EM	440 A	F	1-439	PDB
7QY7	EM	470 A	F	1-439	PDB
7QYA	EM	480 A	F	1-439	PDB
7QYB	EM	410 A	F	1-439	PDB
7W37	EM	300 A	F	1-439	PDB
7W38	EM	310 A	F	1-439	PDB
7W39	EM	320 A	F	1-439	PDB
7W3A	EM	350 A	F	1-439	PDB
7W3B	EM	360 A	F	1-439	PDB
7W3C	EM	340 A	F	1-439	PDB
7W3F	EM	330 A	F	1-439	PDB
7W3G	EM	320 A	F	1-439	PDB
7W3H	EM	320 A	F	1-439	PDB
7W3I	EM	350 A	F	1-439	PDB
7W3J	EM	350 A	F	1-439	PDB
7W3K	EM	360 A	F	1-439	PDB
7W3M	EM	350 A	F	1-439	PDB
8CVT	EM	300 A	F	1-439	PDB
AF-P17980-F1	Predicted				AlphaFoldDB

182 variants for P17980

Variant ID(s)	Position	Change	Description	Diseaes Association	Provenance
rs1340810913 CA380323845	5	P>L		No	ClinGen TOPMed gnomAD
rs753672546 CA221703127	5	P>S		No	ClinGen Ensembl
rs1335890825 CA380323838	6	N>Y		No	ClinGen gnomAD
rs1361948663 CA380323814	7	I>V		No	ClinGen TOPMed
rs988707465 CA221703113	8	E>*		No	ClinGen gnomAD
rs1340695170 CA380323733	10	P>L		No	ClinGen TOPMed
CA380323740 rs1297264196	10	P>S		No	ClinGen TOPMed
CA380323730 rs1158532692	11	V>M		No	ClinGen TOPMed gnomAD
TCGA novel	12	T>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1565677298 CA599374619	13	R>*		No	ClinGen Ensembl
CA380323687 rs1378379681	13	R>P		No	ClinGen TOPMed
CA380323689 rs1378379681	13	R>Q		No	ClinGen TOPMed
rs868175774 CA221703110	15	E>*		No	ClinGen Ensembl
rs956664663 CA221703096	16	K>M		No	ClinGen gnomAD
rs752975567 CA5976426	16	K>N		No	ClinGen ExAC TOPMed gnomAD
rs867941932 CA380323594	18	A>E		No	ClinGen gnomAD
CA221703063 rs867941932	18	A>V		No	ClinGen gnomAD
CA380323520 rs1232330566	22	D>N		No	ClinGen gnomAD
CA380323495 rs1565677231	23	E>A		No	ClinGen Ensembl
CA221703040 rs1049340387	24	A>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
rs900279013 CA221702837	27	D>N		No	ClinGen TOPMed gnomAD
CA380322916 rs1174925152	30	G>R		No	ClinGen TOPMed gnomAD
CA380322885 rs750311677	32	E>D		No	ClinGen ExAC TOPMed gnomAD
CA380322894 rs1472069059	32	E>Q		No	ClinGen gnomAD
CA380322725 rs1313830216	45	T>A		No	ClinGen gnomAD
rs1196122555 CA380322712	46	R>Q		No	ClinGen TOPMed
CA380322714 rs1280839186	46	R>W		No	ClinGen gnomAD
rs1222074899 CA380322683	49	D>N		No	ClinGen gnomAD
rs1595893080 CA380322657	50	S>R		No	ClinGen Ensembl
CA380322640 rs1595893077	52	I>V		No	ClinGen Ensembl
TCGA novel	53	K>N	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA380322487 rs1263717885	58	E>V		No	ClinGen TOPMed
rs1595892906 CA380322458	63	T>P		No	ClinGen Ensembl
rs752556002 CA221702310	66	L>P		No	ClinGen Ensembl
rs1187821591 CA380322426	67	Q>K		No	ClinGen gnomAD
rs148236529 CA5976376	77	S>N		No	ClinGen ESP ExAC TOPMed gnomAD
CA380322236 rs773742401	80	I>M		No	ClinGen ExAC gnomAD
CA221702296 rs371198726	81	K>R		No	ClinGen Ensembl
rs770493899 CA5976374	83	N>K		No	ClinGen ExAC
rs1265080785 CA380322193	84	K>N	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA5976373 rs199670547	85	T>P		No	ClinGen ExAC gnomAD
CA221702281 rs776087841	93	V>I		No	ClinGen TOPMed gnomAD
rs1299178872 CA380322084	94	I>T		No	ClinGen gnomAD
CA380321949 rs1194754191	97	L>Q		No	ClinGen TOPMed
CA380321771 rs1199279072	106	E>K		No	ClinGen gnomAD
CA221701939 COSM291422 rs771618920	110	N>S	large_intestine Variant assessed as Somatic; impact. [Cosmic, NCI-TCGA]	No	ClinGen cosmic curated Ensembl NCI-TCGA
rs1344871576 CA380321679	111	I>V		No	ClinGen TOPMed gnomAD
CA380321547 rs762341488 CA5976354	118	K>N		No	ClinGen ExAC gnomAD
CA380321474 rs1219857571	122	A>G		No	ClinGen TOPMed
rs1326721756 CA380321437	124	I>M		No	ClinGen gnomAD
rs200092114 CA221701936	129	R>*		No	ClinGen TOPMed gnomAD
TCGA novel	129	R>Q	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA5976353 rs777306127	130	Q>H	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
TCGA novel	131	T>A	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs373681287 CA5976336	131	T>M		No	ClinGen ESP ExAC gnomAD
rs962451746 CA221701782	137	I>T		No	ClinGen TOPMed
CA5976333 rs764545358	138	G>E		No	ClinGen ExAC TOPMed gnomAD
rs1410358871 CA380321107	141	D>G		No	ClinGen gnomAD
rs775489238 CA5976331	146	K>E		No	ClinGen ExAC gnomAD
rs767646924 CA5976330	146	K>R		No	ClinGen ExAC TOPMed gnomAD
rs774580136 CA5976328	151	V>L		No	ClinGen ExAC gnomAD
rs1229293901 CA380320086	157	S>F	Variant assessed as Somatic; 4.619e-05 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA380320049 rs1273113578	163	T>M	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
rs1037801545 CA221701490	166	T>I		No	ClinGen Ensembl
rs768505267 CA5976307	167	E>Q		No	ClinGen ExAC gnomAD
rs775517283 CA5976305	171	R>W		No	ClinGen ExAC gnomAD
rs1595892587 CA380319992	172	V>G		No	ClinGen Ensembl
rs1250096161 CA380319967	176	E>Q		No	ClinGen TOPMed
CA380319955 rs1595892584	177	V>G		No	ClinGen Ensembl
CA380319954 rs1422469931	178	D>N		No	ClinGen gnomAD
rs748962337 CA5976300	179	E>K	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA gnomAD
rs1270594616 CA380319939	180	R>G		No	ClinGen gnomAD
rs201014352 CA221701462	182	T>A		No	ClinGen TOPMed gnomAD
CA5976299 rs149581795	182	T>M		No	ClinGen ESP ExAC
rs201014352 CA380319925	182	T>S		No	ClinGen TOPMed gnomAD
CA221701449 rs111347741	183	E>G		No	ClinGen Ensembl
rs768111213 CA5976296	184	Q>R		No	ClinGen ExAC gnomAD
rs1052412219 CA221701414	188	I>T		No	ClinGen Ensembl
TCGA novel	190	G>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1276593437 CA380319824	196	Q>R		No	ClinGen gnomAD
rs1407700250 CA380319781	201	A>T		No	ClinGen gnomAD
rs1309652081 CA380319774	202	I>V		No	ClinGen TOPMed
rs1315478498 CA380319750	205	P>L		No	ClinGen TOPMed
CA221700424 rs1002201129	206	M>V		No	ClinGen Ensembl
rs1315030125 CA380319705	211	K>R		No	ClinGen gnomAD
CA5976278 rs114480768	212	F>L		No	ClinGen 1000Genomes ExAC
CA380319682 rs1388910428	214	N>S	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen NCI-TCGA gnomAD
CA5976275 CA5976274 rs34037785	218	Q>H		No	ClinGen 1000Genomes ESP ExAC TOPMed gnomAD
CA5976272 rs758498353	219	P>L		No	ClinGen ExAC gnomAD
CA380319650 rs1311648735	219	P>S		No	ClinGen TOPMed gnomAD
rs750585848 CA5976271	220	P>S		No	ClinGen ExAC gnomAD
CA380319626 rs1464671161	223	V>L		No	ClinGen gnomAD
CA380319594 rs1158344396	228	P>T		No	ClinGen TOPMed
rs373075759 CA5976266	231	T>M		No	ClinGen ESP ExAC TOPMed gnomAD
rs1443264271 CA380319532	238	R>Q		No	ClinGen TOPMed
rs139347167 CA5976261	242	A>T		No	ClinGen ESP ExAC TOPMed gnomAD
CA221700285 rs11548873	242	A>V		No	ClinGen Ensembl
CA380319435 rs1368885119	246	A>D		No	ClinGen TOPMed
TCGA novel	250	K>T	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1347753543 CA380319369 COSM927438	252	A>V	Variant assessed as Somatic; impact. endometrium [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated NCI-TCGA TOPMed
CA380319302 rs1565675967	258	Q>H		No	ClinGen Ensembl
CA380319169 rs1167854747	267	L>I		No	ClinGen gnomAD
CA380319153 rs1172551557	269	R>Q		No	ClinGen gnomAD
rs762357303 CA5976244	269	R>W		No	ClinGen ExAC gnomAD
CA5976243 rs772721062	271	A>D		No	ClinGen ExAC TOPMed gnomAD
rs761490320 CA5976241	273	A>P		No	ClinGen ExAC gnomAD
CA380319029 rs1205104020 CA380319031	277	E>D		No	ClinGen TOPMed gnomAD
rs146890432 CA221700093	282	I>M		No	ClinGen ESP
rs747411615 CA5976238	283	I>V		No	ClinGen ExAC gnomAD
rs142651885 CA5976237	285	I>T		No	ClinGen ESP ExAC TOPMed gnomAD
CA380318868 rs1225163352	288	L>F		No	ClinGen gnomAD
rs746372081 CA5976235	291	I>V		No	ClinGen ExAC gnomAD
rs1315904259 CA380318007	303	D>N		No	ClinGen gnomAD
CA380317986 rs1317871384	304	R>L		No	ClinGen gnomAD
CA380317990 rs1363348500	304	R>W		No	ClinGen gnomAD
rs1387626473 CA380317982	305	E>K		No	ClinGen gnomAD
CA380317969 rs1424593578	306	V>M		No	ClinGen gnomAD
rs1184966347 CA380317926	310	M>I		No	ClinGen gnomAD
TCGA novel	311	L>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1447112446 CA380317909	313	L>F		No	ClinGen gnomAD
CA380317889 rs1193479431	316	Q>R		No	ClinGen gnomAD
CA380317855 rs1271770605	321	Q>*		No	ClinGen TOPMed
rs1293825290 CA380317852	321	Q>L		No	ClinGen gnomAD
CA221696156 rs368385342	326	V>F		No	ClinGen ESP gnomAD
CA380317820 rs368385342	326	V>L		No	ClinGen ESP gnomAD
CA380317792 rs1595891386	328	V>G		No	ClinGen Ensembl
CA221695960 rs112401194	329	I>M		No	ClinGen Ensembl
rs112305956 CA221695955	330	A>P		No	ClinGen Ensembl
rs1595891374 CA380317748	335	V>G		No	ClinGen Ensembl
CA380317705 rs1431179366	342	L>F		No	ClinGen gnomAD
rs113742075 CA221695929	343	L>H		No	ClinGen Ensembl
rs113742075 CA221695933	343	L>P		No	ClinGen Ensembl
CA380317686 rs1242700261	345	S>L	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed gnomAD
rs1469627112 CA380317657	350	R>C		No	ClinGen gnomAD
CA221695927 rs930073621	350	R>H		No	ClinGen TOPMed gnomAD
rs1259002573 CA380317645	352	I>V		No	ClinGen TOPMed
rs778892792 CA5976189	355	P>L		No	ClinGen ExAC TOPMed gnomAD
rs753776335 CA5976187	356	M>V		No	ClinGen ExAC gnomAD
rs372425706 CA5976186	358	N>S		No	ClinGen ESP ExAC TOPMed gnomAD
CA5976185 rs755642234	359	E>K		No	ClinGen ExAC gnomAD
rs1210812650 CA380317575	362	R>Q		No	ClinGen TOPMed
CA5976183 rs149054498	362	R>W		No	ClinGen ESP ExAC gnomAD
CA5976182 rs759932695	365	I>V		No	ClinGen ExAC
rs144968726 CA5976180	366	M>L		No	ClinGen ESP ExAC TOPMed gnomAD
rs144968726 CA5976181	366	M>V		No	ClinGen ESP ExAC TOPMed gnomAD
rs763516120 CA5976179	370	S>F		No	ClinGen ExAC gnomAD
rs773880647 CA380317517	371	R>*		No	ClinGen ExAC gnomAD
rs1565675030 CA380317491	374	N>S		No	ClinGen Ensembl
rs998816001 CA221694299	378	D>H		No	ClinGen TOPMed gnomAD
CA221694297 rs143985735	379	V>M		No	ClinGen ESP TOPMed gnomAD
rs780529228 CA5976147	382	E>K		No	ClinGen ExAC gnomAD
TCGA novel	383	E>D	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	384	L>M	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
rs1364926218 CA380317191	385	A>T		No	ClinGen gnomAD
CA5976146 rs754539699	386	R>C		No	ClinGen ExAC TOPMed gnomAD
CA5976144 rs779894566	386	R>H	Variant assessed as Somatic; 0.0 impact. [NCI-TCGA]	No	ClinGen ExAC NCI-TCGA TOPMed gnomAD
CA5976145 rs779894566	386	R>L		No	ClinGen ExAC TOPMed gnomAD
CA5976143 rs758833100	388	T>I		No	ClinGen ExAC gnomAD
rs1001225780 CA221694279	389	D>A		No	ClinGen TOPMed
rs1001225780 CA380317129	389	D>G		No	ClinGen TOPMed
CA5976142 rs750879646	389	D>N		No	ClinGen ExAC gnomAD
rs765706831 CA5976141	390	D>A		No	ClinGen ExAC gnomAD
CA5976140 rs757634277	392	N>S		No	ClinGen ExAC TOPMed gnomAD
rs757634277 CA221694264	392	N>T		No	ClinGen ExAC TOPMed gnomAD
TCGA novel	394	A>P	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
TCGA novel	399	V>M	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA5976138 rs764028067	400	C>Y		No	ClinGen ExAC gnomAD
rs895209304 CA221694198	403	A>V	Variant assessed as Somatic; impact. [NCI-TCGA]	No	ClinGen NCI-TCGA TOPMed
COSM1354080 CA380316823 rs1471140987	407	A>T	Variant assessed as Somatic; 0.0 impact. large_intestine [NCI-TCGA, Cosmic]	No	ClinGen cosmic curated NCI-TCGA TOPMed gnomAD
rs1027643207 CA221693954	409	R>C		No	ClinGen TOPMed gnomAD
rs199874053 CA221693951	409	R>H		No	ClinGen gnomAD
rs776430838 CA5976110	410	R>K		No	ClinGen ExAC TOPMed gnomAD
rs1273800761 CA380316753	412	A>T		No	ClinGen TOPMed
CA380316736 rs1252054308	413	T>M		No	ClinGen gnomAD
rs1304723915 CA380316697	415	L>P		No	ClinGen TOPMed gnomAD
CA380316578 rs1210231658	421	M>I		No	ClinGen TOPMed
TCGA novel	425	L>M	Variant assessed as Somatic; impact. [NCI-TCGA]	No	NCI-TCGA
CA5976106 rs771734810	432	K>N		No	ClinGen ExAC gnomAD
rs1291484322 CA380316394	434	N>S		No	ClinGen gnomAD
rs745466725 CA5976104	436	Q>L		No	ClinGen ExAC gnomAD
CA380316334 rs1442875283	439	A>T		No	ClinGen Ensembl
rs372963006 CA5976102	440	A>S		No	ClinGen ESP ExAC TOPMed gnomAD

1 associated diseases with P17980

[MIM: 619354]: Deafness, cataract, impaired intellectual development, and polyneuropathy (DCIDP)

An autosomal recessive disease characterized by early onset of deafness, cataract, severe developmental delay, and severely impaired intellectual development. Patients later develop polyneuropathy of the lower extremities, associated with depigmentation of the hair in that area. {ECO:0000269|PubMed:32500975}. Note=The disease may be caused by variants affecting the gene represented in this entry.

Without disease ID

An autosomal recessive disease characterized by early onset of deafness, cataract, severe developmental delay, and severely impaired intellectual development. Patients later develop polyneuropathy of the lower extremities, associated with depigmentation of the hair in that area. {ECO:0000269|PubMed:32500975}. Note=The disease may be caused by variants affecting the gene represented in this entry.

5 regional properties for P17980

Type	Name	Position	InterPro Accession
domain	Aminoacyl-tRNA synthetase, class II (D/K/N)	236 - 585	IPR004364
domain	OB-fold nucleic acid binding domain, AA-tRNA synthetase-type	108 - 183	IPR004365
domain	Aminoacyl-tRNA synthetase, class II	258 - 583	IPR006195
domain	Lysyl-tRNA synthetase, class II, C-terminal	251 - 586	IPR018149
domain	Lysine-tRNA ligase, class II, N-terminal	106 - 248	IPR044136

Functions

		Description
EC Number
Subcellular Localization	Cytoplasm Nucleus	Colocalizes with TRIM5 in the cytoplasmic bodies
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category	No pathway information available

11 GO annotations of cellular component

Name	Definition
cytosol	The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes.
extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
ficolin-1-rich granule lumen	Any membrane-enclosed lumen that is part of a ficolin-1-rich granule.
membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
nucleoplasm	That part of the nuclear content other than the chromosomes or the nucleolus.
nucleus	A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent.
P-body	A focus in the cytoplasm where mRNAs may become inactivated by decapping or some other mechanism. Protein and RNA localized to these foci are involved in mRNA degradation, nonsense-mediated mRNA decay (NMD), translational repression, and RNA-mediated gene silencing.
proteasome accessory complex	A protein complex, that caps one or both ends of the proteasome core complex and regulates entry into, or exit from, the proteasome core complex.
proteasome complex	A large multisubunit complex which catalyzes protein degradation, found in eukaryotes, archaea and some bacteria. In eukaryotes, this complex consists of the barrel shaped proteasome core complex and one or two associated proteins or complexes that act in regulating entry into or exit from the core.
proteasome regulatory particle, base subcomplex	The subcomplex of the proteasome regulatory particle that directly associates with the proteasome core complex.
secretory granule lumen	The volume enclosed by the membrane of a secretory granule.

4 GO annotations of molecular function

Name	Definition
ATP binding	Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
ATP hydrolysis activity	Catalysis of the reaction: ATP + H2O = ADP + H+ phosphate. ATP hydrolysis is used in some reactions as an energy source, for example to catalyze a reaction or drive transport against a concentration gradient.
identical protein binding	Binding to an identical protein or proteins.
proteasome-activating activity	Catalysis of the reaction: ATP + H2O = ADP + phosphate, which promotes unfolding of protein substrates, and channel opening of the core proteasome.

4 GO annotations of biological process

Name	Definition
modulation by host of viral transcription	Any process in which a host organism modulates the frequency, rate or extent of viral transcription.
positive regulation of proteasomal protein catabolic process	Any process that activates or increases the frequency, rate or extent of proteasomal protein catabolic process.
positive regulation of transcription by RNA polymerase II	Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter.
proteasome-mediated ubiquitin-dependent protein catabolic process	The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.

9 homologous proteins in AiPD

UniProt AC	Gene Name	Protein Name	Species	Evidence Code
P62333	PSMC6	26S proteasome regulatory subunit 10B	Homo sapiens (Human)	PR
P43686	PSMC4	26S proteasome regulatory subunit 6B	Homo sapiens (Human)	PR
P35998	PSMC2	26S proteasome regulatory subunit 7	Homo sapiens (Human)	PR
P62195	PSMC5	26S proteasome regulatory subunit 8	Homo sapiens (Human)	PR
O88685	Psmc3	26S proteasome regulatory subunit 6A	Mus musculus (Mouse)	PR
Q63569	Psmc3	26S proteasome regulatory subunit 6A	Rattus norvegicus (Rat)	PR
P46465	TBP1	26S proteasome regulatory subunit 6A homolog	Oryza sativa subsp japonica (Rice)	PR
Q9SEI2	RPT5A	26S proteasome regulatory subunit 6A homolog A	Arabidopsis thaliana (Mouse-ear cress)	PR
P54776	TBP1	26S proteasome regulatory subunit 6A homolog	Solanum lycopersicum (Tomato) (Lycopersicon esculentum)	PR

10	20	30	40	50	60
MNLLPNIESP	VTRQEKMATV	WDEAEQDGIG	EEVLKMSTEE	IIQRTRLLDS	EIKIMKSEVL
70	80	90	100	110	120
RVTHELQAMK	DKIKENSEKI	KVNKTLPYLV	SNVIELLDVD	PNDQEEDGAN	IDLDSQRKGK
130	140	150	160	170	180
CAVIKTSTRQ	TYFLPVIGLV	DAEKLKPGDL	VGVNKDSYLI	LETLPTEYDS	RVKAMEVDER
190	200	210	220	230	240
PTEQYSDIGG	LDKQIQELVE	AIVLPMNHKE	KFENLGIQPP	KGVLMYGPPG	TGKTLLARAC
250	260	270	280	290	300
AAQTKATFLK	LAGPQLVQMF	IGDGAKLVRD	AFALAKEKAP	SIIFIDELDA	IGTKRFDSEK
310	320	330	340	350	360
AGDREVQRTM	LELLNQLDGF	QPNTQVKVIA	ATNRVDILDP	ALLRSGRLDR	KIEFPMPNEE
370	380	390	400	410	420
ARARIMQIHS	RKMNVSPDVN	YEELARCTDD	FNGAQCKAVC	VEAGMIALRR	GATELTHEDY
430
MEGILEVQAK	KKANLQYYA